Skyline Diagnostics
SkylineDx, Flanders Institute of Biotechnology Partner to Validate Immunotherapy Response Biomarkers
Researchers will assess biomarkers in four clinical trials by mapping the tumor microenvironment using single-cell technology.
SkylineDx, NeraCare Partnering on Proteomic Test for Melanoma
The companies inked a codevelopment and licensing agreement for NeraCare's Immunoprint test for identifying high-risk early-stage melanoma patients.
SkylineDx Gains CE-IVD Mark for Melanoma Metastasis Risk Assay
The Netherlands-based firm is partnering with Belgian company Biocartis on European commercialization of the qPCR assay, which could reduce unnecessary surgeries.
SkylineDx, VIB Form Molecular Diagnostics Partnership
The partnership will focus on high-potential in vitro diagnostic opportunities for unmet medical needs for global markets.
Biocartis, SkylineDx Partner to Develop Melanoma Nodal Metastasis Risk Test
The Belgian molecular diagnostics firm also reported a 70 percent year-over-year increase in commercial cartridge volumes in the first quarter.
Sep 3, 2019
SkylineDx Secures $21.9M Investment
Apr 18, 2017
Nov 25, 2015
SkylineDx Lands CE-IVD Mark for MMProfiler
Jan 2, 2013
Jun 26, 2012
Jul 26, 2011
Jul 6, 2011